Woldeamanuel Gashaw Garedew, Wondimu Diresibachew Haile
1Department of Medicine, College of Medicine and Health Sciences, Wolkite University, P.O. Box 07, Wolkite, Ethiopia.
2Department of Medical Physiology, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
BMC Hematol. 2018 Mar 15;18:7. doi: 10.1186/s12878-018-0099-y. eCollection 2018.
Anemia is the most common hematological abnormality in Human immunodeficiency virus (HIV) positive patients and a significant predictor of its progression to AIDS or death. This study was aimed to assess the prevalence of anemia before and after initiation of antiretroviral therapy (ART) among HIV positive patients attending Black Lion Specialized Hospital, Addis Ababa, Ethiopia.
A cross sectional study was conducted from January to April, 2017 in Black Lion Specialized Hospital, Addis Ababa, Ethiopia. A total of 255 patients on ART were selected using simple random sampling techniques. Socio-demographic and clinical characteristics of the study subjects were collected using structured questionnaire. Measurements of complete blood cell counts and CD4 + T cell counts were made using Sysmex XT 2000i hematology analyzer and BD FACS Count CD4 analyzer, respectively. Statistical analysis of the data (Chi-square, paired T-test, logistic regression) was done using SPSS version 20. A -value < 0.05 was considered as significant.
Prevalence of anemia before and after ART initiation was 41.9 and 11.4% respectively. There are a significance differences in CD4 + T cell count, RBC count, hemoglobin values and RBC indices in HIV patients before and after ART initiation (-value < 0.05). WHO clinical stages and CD4+ T cell counts were found to be associated with the prevalence of anemia before ART initiation. Among the total number of anemic cases, normocytic normochromic anemia was present in 71% of the cases before ART and in 58.6% of the cases after ART. The prevalence of macrocytic normochromic anemia before and after ART initiation was 4.7 and 27.6% respectively.
It is evident from this study that there is a remarkable reduction in the prevalence of anemia after ART initiation. However, a significant proportion of HIV patients remained anemic after 6 months of ART initiation suggesting the need for routine screening and proper treatment of anemia to mitigate its adverse effects.
贫血是人类免疫缺陷病毒(HIV)阳性患者中最常见的血液学异常,也是其进展为获得性免疫缺陷综合征(AIDS)或死亡的重要预测指标。本研究旨在评估埃塞俄比亚亚的斯亚贝巴黑狮专科医院接受抗逆转录病毒治疗(ART)的HIV阳性患者在开始ART前后贫血的患病率。
2017年1月至4月在埃塞俄比亚亚的斯亚贝巴黑狮专科医院进行了一项横断面研究。采用简单随机抽样技术共选取255例接受ART的患者。使用结构化问卷收集研究对象的社会人口学和临床特征。分别使用Sysmex XT 2000i血液分析仪和BD FACS Count CD4分析仪进行全血细胞计数和CD4 + T细胞计数测量。使用SPSS 20版对数据进行统计分析(卡方检验、配对t检验、逻辑回归)。P值<0.05被认为具有统计学意义。
开始ART前后贫血的患病率分别为41.9%和11.4%。HIV患者开始ART前后的CD4 + T细胞计数、红细胞计数、血红蛋白值和红细胞指数存在显著差异(P值<0.05)。发现世界卫生组织临床分期和CD4 + T细胞计数与开始ART前贫血的患病率相关。在所有贫血病例中,正细胞正色素性贫血在开始ART前的病例中占71%,在开始ART后的病例中占58.6%。开始ART前后大细胞正色素性贫血的患病率分别为4.7%和27.6%。
本研究表明,开始ART后贫血的患病率显著降低。然而,相当一部分HIV患者在开始ART 6个月后仍贫血,这表明需要对贫血进行常规筛查和适当治疗,以减轻其不良影响。